Published on
June 8, 2018
- 15:00 GMT
Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the 41st European Cystic Fibrosis ...
ELX-02 demonstrated dose-dependent rescue of CFTR function in human bronchial epithelial cells (HBEs) and organoids from patients carrying at least one nonsense CFTR mutation Eloxx expects to initiate a Phase 2 clinical trial later this year for ELX-02 in …
Distribution channels:
Conferences & Trade Fairs, Technology
...
